Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Thyroid Gland Papillary Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00098813
What this trial is testing

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

Who this might be right for
Recurrent Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid Cancer
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Looking for participantsNCT06959641
What this trial is testing

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced Differentiated Thyroid Gland CarcinomaLocally Advanced Poorly Differentiated Thyroid Gland CarcinomaLocally Advanced Thyroid Gland Follicular Carcinoma+18 more
Jochen Lorch 33
Testing effectiveness (Phase 2)Study completedNCT00026533
What this trial is testing

Thalidomide in Treating Patients With Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Kenneth Ain
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Large-scale testing (Phase 3)Active Not RecruitingNCT03690388
What this trial is testing

Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Who this might be right for
Differentiated Thyroid Cancer
Exelixis 187
Testing effectiveness (Phase 2)Active Not RecruitingNCT02152995
What this trial is testing

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Who this might be right for
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+9 more
National Cancer Institute (NCI) 34
Testing effectiveness (Phase 2)Study completedNCT00389441
What this trial is testing

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Pfizer 52
Not applicableStudy completedNCT01534897
What this trial is testing

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Who this might be right for
Papillary Thyroid Carcinoma
Massachusetts General Hospital 10
Testing effectiveness (Phase 2)Study completedNCT00559949
What this trial is testing

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Who this might be right for
Recurrent Thyroid Gland CarcinomaStage I Thyroid Gland Papillary CarcinomaStage II Thyroid Gland Papillary Carcinoma+2 more
National Cancer Institute (NCI) 39